Takedas Pharmaceuticals chief executive Takashi Iizuka has told a Japanese parliamentary committee that he has been in medicine for “20 years”.
Speaking during a parliamentary hearing into Japan’s drug market, the former CEO of Japanese pharmaceutical company Takedah announced he had been in pharmaceutical sales for the last 20 years, adding that he believes there are still opportunities for the country’s pharmaceutical sector.
The chairman of the committee, Yuki Ohta, told Takedahs head Iizaban that the drug industry is “the biggest employer” of Japanese workers.
“It’s hard to understand how I could be the CEO of a company that has produced and sold medicines for 20 years,” Iizan said.
The meeting was the first time the chairman of a committee had been able to speak directly to the CEO.
In October, Takedha had to cut more than $1bn (£700m) in profits after a drug-maker said the company had failed to provide adequate information to regulators about the drug.
Takeda is currently seeking regulatory approval for its latest drug, N-acetylcysteine (NAC), which is due to be released on April 12.
The company has also been battling a patent battle with a rival, NAC Therapeutics, in the US.
“Takedah Pharmaceuticals is committed to ensuring that the NAC product is developed and delivered to the US market in a manner consistent with Japanese regulation and the laws of Japan,” the company said in a statement on Monday.